FUJIFILM Diosynth Biotechnologies welcomed UK Prime Minister Boris Johnson to Teesside at its Billingham site
on Saturday 13 February to meet the team working to support the manufacture of a COVID-19 vaccine candidate.

FUJIFILM Diosynth Biotechnologies has begun production of two different COVID-19 vaccine candidates in Texas
with support from the U.S. government to meet Operation Warp Speed goals.

Process development and manufacture of formulations using lipid nanoparticle technology.

FUJIFILM Diosynth Biotechnologies will manufacture antigen component of Novavax’ COVID-19 vaccine candidate at its site in Billingham, UK, from beginning of Q1, 2021.

FUJIFILM Diosynth Biotechnologies Texas Facility will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed.

Novavax, Inc. and FUJIFILM Diosynth Biotechnologies have announced an agreement to manufacture bulk drug substance for Novavax’ COVID-19 vaccine candidate.